Google
CATX — PERSPECTIVE THERAPEUTICS INC. (Healthcare >> Medical Devices)
CATX FAQ
What is CATX's ROE?
PERSPECTIVE THERAPEUTICS INC. reports a Return on Equity (ROE) of -31.99%.
What is CATX's dividend yield?
PERSPECTIVE THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is CATX's Deepscope Quality Score?
Deepscope rates CATX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CATX?
Deepscope's AI Timing Score for CATX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CATX belong to?
PERSPECTIVE THERAPEUTICS INC. is classified under the Healthcare >> Medical Devices sector on the NYSE MKT exchange.
|
USD 2.93
Price
-0.10
(-3.30%)
Day Change
|
|
|---|
CATX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 78 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.93 |
| PBV / Sector |
0.96 / 7.41
GREAT
|
| Earning Per Share | -0.97 |
| PE / Sector |
N/A / 28.89
|
| PEG or PE/Growth / Sector |
N/A / 0.39
|
| Average 1M Daily Value |
4.51 M
GREAT
|
| Average 1W Daily Value |
5.54 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-09 09:39:45 |
| Symbol | CATX |
| Name | PERSPECTIVE THERAPEUTICS INC. |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE MKT |
| Listed Shares | 114.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 334.73 / 18,405.70 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2401 Elliott Avenue, Seattle, WA, United States, 98121
Phone: 206 676 0900
Website: https://www.perspectivetherapeutics.com
Employees: 163
Sector: Healthcare >> Medical Devices
Description: Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
